Condition: Chronic Graft-versus-host-disease · Sponsor: Incyte Corporation
This study will be conducted to evaluate the safety, efficacy, and pharmacokinetics of axatilimab monotherapy in Chinese participants with recurrent or refractory active chronic graft-versus-host disease after systemic therapy.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Peking University People'S Hospital | Beijing, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, China | Recruiting |
| The Second Affiliated Hospital, Army Medical University (Xinqiao Hospital) | Chongoing, China | Recruiting |
| Zhujiang Hospital of Southern Medical University | Guangzhou, China | Recruiting |
| Nanfang Hospital of Southern Medical University | Guangzhou, China | Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| Shanghai Children'S Medical Center | Shanghai, China | Recruiting |
| Institute of Hematology, Chinese Academy of Medical Sciences | Tianjin, China | Recruiting |
| Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06843408